# Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

> **NCT05861271** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 1008 (estimated)

## Conditions studied

- Breast Cancer Stage I

## Interventions

- **DRUG:** Capecitabine，Pyrotinib

## Key facts

- **NCT ID:** NCT05861271
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 1008 (ESTIMATED)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861271, "Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05861271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*